Compare NTRS & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTRS | TEVA |
|---|---|---|
| Founded | 1889 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5B | 30.2B |
| IPO Year | N/A | N/A |
| Metric | NTRS | TEVA |
|---|---|---|
| Price | $142.68 | $33.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $144.69 | $37.25 |
| AVG Volume (30 Days) | 1.0M | ★ 7.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.09 | N/A |
| Revenue Next Year | $4.26 | $2.97 |
| P/E Ratio | ★ $16.88 | $28.19 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $81.62 | $12.47 |
| 52 Week High | $157.60 | $37.35 |
| Indicator | NTRS | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 51.50 |
| Support Level | $139.57 | $30.70 |
| Resistance Level | $157.60 | $35.32 |
| Average True Range (ATR) | 4.68 | 0.82 |
| MACD | -0.66 | -0.22 |
| Stochastic Oscillator | 24.99 | 27.41 |
Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of December 2024, Northern Trust had assets under custody or administration of $16.8 trillion and assets under management of $1.6 trillion.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.